Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...

See the charts that show why Moderna's vaccine may offer protection longer than Pfizer and J&J's shots; This person stayed at a free 10-day quarantine hotel in NYC when they got COVID-19 ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Booster doses are most recommended for adults age 65 and up, who don't generally have the same kind of strong, lasting immune response to vaccines as younger people. More evidence is beginning to ...

Moderna said it plans to cut $1.1 billion in expenses by 2027 as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product ...

Get a deeper insight into the potential performance of Moderna (MRNA) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates ...